# |
Study |
1 |
Safety Study of a Cell-based Cancer Vaccine in Melanoma
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Melanoma, Effects of Immunotherapy, Tumor Vaccines |
Start date |
May 2013 |
End date |
November 2016 |
Study type |
INTERVENTIONAL |
Interventions |
GeniusVac-Mel4 |
NCT number |
NCT01863108 |
Go to top of page
|
2 |
Sipuleucel-T Manufacturing Demonstration Study
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Prostate Neoplasms, Neoplasms, Prostate, Prostatic Cancer, Neoplasms, Prostatic, Prostate Cancer, Cancer of the Prostate, Cancer of Prostate |
Start date |
June 2012 |
End date |
January 2014 |
Study type |
INTERVENTIONAL |
Interventions |
sipuleucel-T |
NCT number |
NCT01477749 |
Go to top of page
|
3 |
Study of DC Vaccination Against Glioblastoma
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Glioblastoma Multiforme, Neoplasms, Glioma |
Start date |
March 2012 |
End date |
July 2014 |
Study type |
INTERVENTIONAL |
Interventions |
Radiotherapy, Chemotherapy, blank placebo, surgery, DC vaccination |
NCT number |
NCT01567202 |
Go to top of page
|
4 |
A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Metastatic Renal Cell Carcinoma |
Start date |
February 2012 |
End date |
June 2013 |
Study type |
INTERVENTIONAL |
Interventions |
Combig-DC (allogeneic dendritic cells) Cancer Vaccine |
NCT number |
NCT01525017 |
Go to top of page
|
5 |
To Identify HLA-A1101-restricted Peptide Epitopes Derived From Novel Oncoantigens (URLC10, KIF20A, and CDCA1) Applicable for Cancer Vaccine in Singapore
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Anonymous Donors at Blood Donation Center (NUH) |
Start date |
January 2012 |
End date |
Unspecified |
Study type |
OBSERVATIONAL |
Interventions |
|
NCT number |
NCT01570439 |
Go to top of page
|
6 |
Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Prostatic Neoplasms |
Start date |
October 2011 |
End date |
October 2012 |
Study type |
INTERVENTIONAL |
Interventions |
mRNA transfected dendritic cell, Docetaxel |
NCT number |
NCT01446731 |
Go to top of page
|
7 |
Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Colorectal Neoplasms |
Start date |
August 2011 |
End date |
August 2014 |
Study type |
INTERVENTIONAL |
Interventions |
Supportive treatment, dendritic cell vaccine |
NCT number |
NCT01413295 |
Go to top of page
|
8 |
Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Recurrent Epithelial Ovarian Cancer |
Start date |
April 2011 |
End date |
April 2022 |
Study type |
INTERVENTIONAL |
Interventions |
DC-006 vaccine |
NCT number |
NCT01334047 |
Go to top of page
|
9 |
Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Stage III Breast Cancer, Stage II Breast Cancer |
Start date |
February 2011 |
End date |
December 2013 |
Study type |
INTERVENTIONAL |
Interventions |
Autologous dendritic cell vaccination. Dendritic cells are pulsed with their own tumor antigens |
NCT number |
NCT01431196 |
Go to top of page
|
10 |
Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Wilm’s Tumor, Ewing’s Sarcoma, Glioma, Neuroblastoma, Retinoblastoma |
Start date |
February 2011 |
End date |
September 2013 |
Study type |
INTERVENTIONAL |
Interventions |
racotumomab |
NCT number |
NCT01598454 |
Go to top of page
|
11 |
Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Colorectal Carcinoma, Hepatic Metastasis |
Start date |
November 2010 |
End date |
June 2014 |
Study type |
INTERVENTIONAL |
Interventions |
Dendritic cells vaccine |
NCT number |
NCT01348256 |
Go to top of page
|
12 |
Vaccine Therapy in Curative Resected Prostate Cancer Patients
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Prostate Cancer |
Start date |
September 2010 |
End date |
September 2021 |
Study type |
INTERVENTIONAL |
Interventions |
dendritic cell vaccine |
NCT number |
NCT01197625 |
Go to top of page
|
13 |
Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Melanoma |
Start date |
September 2010 |
End date |
Unspecified |
Study type |
INTERVENTIONAL |
Interventions |
Theravac |
NCT number |
NCT01331915 |
Go to top of page
|
14 |
Dendritic Cell Cancer Vaccine for High-grade Glioma
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Glioblastoma Multiforme |
Start date |
March 2010 |
End date |
December 2012 |
Study type |
INTERVENTIONAL |
Interventions |
Temozolomide, Surgery, Radiotherapy, Trivax, Temozolomide, Surgery, Radiotherapy |
NCT number |
NCT01213407 |
Go to top of page
|
15 |
Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Non Small Cell Lung Cancer |
Start date |
December 2009 |
End date |
December 2014 |
Study type |
INTERVENTIONAL |
Interventions |
Dex2 |
NCT number |
NCT01159288 |
Go to top of page
|
16 |
Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Breast Cancer, Malignant Melanoma |
Start date |
September 2009 |
End date |
September 2012 |
Study type |
INTERVENTIONAL |
Interventions |
DC vaccine |
NCT number |
NCT00978913 |
Go to top of page
|
17 |
DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Renal Cell Carcinoma |
Start date |
March 2009 |
End date |
December 2015 |
Study type |
INTERVENTIONAL |
Interventions |
DC-CIK, IL-2/IFN-α |
NCT number |
NCT00862303 |
Go to top of page
|
18 |
Plasmacytoid Dendritic Cell Vaccines in Metastatic Melanoma Patients
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
|
Start date |
February 2008 |
End date |
December 2013 |
Study type |
INTERVENTIONAL |
Interventions |
|
NCT number |
NCT01690377 |
Go to top of page
|
19 |
Generation of Dendritic Cell Precursors From Cord Blood Stem Cells
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Normal Full-Term Deliveries |
Start date |
January 2007 |
End date |
December 2010 |
Study type |
INTERVENTIONAL |
Interventions |
Normal full-term deliveries |
NCT number |
NCT00731744 |
Go to top of page
|
20 |
Dendritic Cell Vaccine in HIV-1 Infection
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
HIV Infections |
Start date |
November 2006 |
End date |
December 2009 |
Study type |
INTERVENTIONAL |
Interventions |
dendritic cell vaccine |
NCT number |
NCT00402142 |
Go to top of page
|
21 |
Impaired Immunity in Patients With Cancer: Influence of Cancer Stage, Chemotherapy, and Cytomegalovirus Infection
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Neoplasms |
Start date |
October 2006 |
End date |
December 2009 |
Study type |
INTERVENTIONAL |
Interventions |
Immune profiling and DC vaccine |
NCT number |
NCT00521287 |
Go to top of page
|
22 |
The Role of Peptide-Loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Metastatic Melanoma |
Start date |
December 2005 |
End date |
Unspecified |
Study type |
INTERVENTIONAL |
Interventions |
Immunotherapy treatment for melanoma |
NCT number |
NCT00279058 |
Go to top of page
|
23 |
Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Lymphoma |
Start date |
September 2003 |
End date |
Unspecified |
Study type |
INTERVENTIONAL |
Interventions |
autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine, autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine, autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine |
NCT number |
NCT00937183 |
Go to top of page
|
24 |
Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Melanoma (Skin) |
Start date |
July 2003 |
End date |
Unspecified |
Study type |
INTERVENTIONAL |
Interventions |
recombinant MAGE-3.1 antigen, survivin antigen, MART-1 antigen, keyhole limpet hemocyanin, therapeutic autologous dendritic cells |
NCT number |
NCT00074230 |
Go to top of page
|
25 |
Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs)
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Cervical Cancer |
Start date |
January 2003 |
End date |
March 2006 |
Study type |
INTERVENTIONAL |
Interventions |
HPV16 E7 peptide-pulsed autologous DCs |
NCT number |
NCT00155766 |
Go to top of page
|
26 |
Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes
Status |
Currently-recruiting |
Phase |
Unspecified |
Conditions |
Melanoma (Skin) |
Start date |
October 2002 |
End date |
Unspecified |
Study type |
INTERVENTIONAL |
Interventions |
dendritic cell-idiotype-keyhole limpet hemocyanin vaccine, HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine, autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine, autologous melanoma lysate-pulsed autologous dendritic cell vaccine, flow cytometry, adjuvant therapy, HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine |
NCT number |
NCT01082198 |
Go to top of page
|
# |
Study |
1 |
Proteome-based Personalized Immunotherapy of Glioblastoma
Status |
Active-but-not-recruiting |
Phase |
Unspecified |
Conditions |
|
Start date |
December 2012 |
End date |
December 2017 |
Study type |
INTERVENTIONAL |
Interventions |
|
NCT number |
NCT01759810 |
Go to top of page
|
2 |
Proteome-based Immunotherapy of Brain Metastases From Breast Cancer
Status |
Active-but-not-recruiting |
Phase |
Unspecified |
Conditions |
Neoplasm Metastasis |
Start date |
December 2012 |
End date |
December 2017 |
Study type |
INTERVENTIONAL |
Interventions |
Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes, Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes |
NCT number |
NCT01782274 |
Go to top of page
|
3 |
Proteome-based Immunotherapy of Lung Cancer Brain Metastases
Status |
Active-but-not-recruiting |
Phase |
Unspecified |
Conditions |
Neoplasm Metastasis |
Start date |
December 2012 |
End date |
December 2017 |
Study type |
INTERVENTIONAL |
Interventions |
Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes, Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes |
NCT number |
NCT01782287 |
Go to top of page
|
4 |
Safety of Active Immunotherapy in Subjects With Ovarian Cancer
Status |
Active-but-not-recruiting |
Phase |
Unspecified |
Conditions |
Ovarian Epithelial Cancer |
Start date |
September 2010 |
End date |
April 2013 |
Study type |
INTERVENTIONAL |
Interventions |
Procure |
NCT number |
NCT01456065 |
Go to top of page
|
5 |
Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients
Status |
Active-but-not-recruiting |
Phase |
Unspecified |
Conditions |
Melanoma |
Start date |
April 2010 |
End date |
January 2013 |
Study type |
INTERVENTIONAL |
Interventions |
autologous dendritic cell vaccine |
NCT number |
NCT01530698 |
Go to top of page
|
6 |
A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Status |
Active-but-not-recruiting |
Phase |
Unspecified |
Conditions |
Melanoma |
Start date |
December 2009 |
End date |
September 2014 |
Study type |
INTERVENTIONAL |
Interventions |
TriMix-DC |
NCT number |
NCT01066390 |
Go to top of page
|
7 |
Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection
Status |
Active-but-not-recruiting |
Phase |
Unspecified |
Conditions |
Glioblastoma Multiforme |
Start date |
October 2009 |
End date |
June 2014 |
Study type |
INTERVENTIONAL |
Interventions |
Autologous Dendritic Cells |
NCT number |
NCT01006044 |
Go to top of page
|
8 |
Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma
Status |
Active-but-not-recruiting |
Phase |
Unspecified |
Conditions |
Metastatic Malignant Melanoma |
Start date |
August 2009 |
End date |
August 2020 |
Study type |
INTERVENTIONAL |
Interventions |
Temozolomide, Dendritic cells – transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion |
NCT number |
NCT00961844 |
Go to top of page
|
9 |
Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients
Status |
Active-but-not-recruiting |
Phase |
Unspecified |
Conditions |
Melanoma |
Start date |
June 2009 |
End date |
June 2015 |
Study type |
INTERVENTIONAL |
Interventions |
autologous dendritic cell vaccination |
NCT number |
NCT00940004 |
Go to top of page
|
10 |
Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma
Status |
Active-but-not-recruiting |
Phase |
Unspecified |
Conditions |
Glioblastoma, Brain Tumor |
Start date |
January 2009 |
End date |
October 2015 |
Study type |
INTERVENTIONAL |
Interventions |
Dendritic cell vaccine with mRNA from tumor stem cells |
NCT number |
NCT00846456 |
Go to top of page
|
11 |
Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer
Status |
Active-but-not-recruiting |
Phase |
Unspecified |
Conditions |
Head and Neck Cancer |
Start date |
November 2007 |
End date |
Unspecified |
Study type |
INTERVENTIONAL |
Interventions |
celecoxib, laboratory biomarker analysis, immunoenzyme technique, flow cytometry, Ad5F35-LMP1/LMP2-transduced autologous dendritic cells |
NCT number |
NCT00589186 |
Go to top of page
|
12 |
Cytotoxicity Induced by Tumor Lysate Pulsed Dendritic Cells Against Autologous Hepatocellular Carcinoma Cells
Status |
Active-but-not-recruiting |
Phase |
Unspecified |
Conditions |
Carcinoma, Hepatocellular |
Start date |
June 2005 |
End date |
June 2006 |
Study type |
INTERVENTIONAL |
Interventions |
DC vaccine |
NCT number |
NCT00327496 |
Go to top of page
|
13 |
Vaccine Therapy in Treating Patients With Stage IV Melanoma
Status |
Active-but-not-recruiting |
Phase |
Unspecified |
Conditions |
Melanoma (Skin) |
Start date |
April 2005 |
End date |
Unspecified |
Study type |
INTERVENTIONAL |
Interventions |
therapeutic autologous dendritic cells, autologous tumor cell vaccine |
NCT number |
NCT00126685 |
Go to top of page
|
14 |
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Status |
Active-but-not-recruiting |
Phase |
Unspecified |
Conditions |
Melanoma (Skin) |
Start date |
October 2002 |
End date |
Unspecified |
Study type |
INTERVENTIONAL |
Interventions |
therapeutic autologous dendritic cells, recombinant CD40-ligand, denileukin diftitox |
NCT number |
NCT00056134 |
Go to top of page
|
15 |
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Status |
Active-but-not-recruiting |
Phase |
Unspecified |
Conditions |
Melanoma (Skin) |
Start date |
October 2002 |
End date |
Unspecified |
Study type |
INTERVENTIONAL |
Interventions |
recombinant CD40-ligand, therapeutic autologous dendritic cells |
NCT number |
NCT00053391 |
Go to top of page
|
# |
Study |
1 |
p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer
Status |
Completed |
Phase |
Unspecified |
Conditions |
Ovarian Cancer |
Start date |
October 2008 |
End date |
July 2009 |
Study type |
INTERVENTIONAL |
Interventions |
P53-SLP vaccine, cyclophosphamide |
NCT number |
NCT00844506 |
Go to top of page
|
2 |
Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission
Status |
Completed |
Phase |
Unspecified |
Conditions |
Leukemia |
Start date |
June 2008 |
End date |
Unspecified |
Study type |
INTERVENTIONAL |
Interventions |
therapeutic autologous dendritic cells |
NCT number |
NCT00963521 |
Go to top of page
|
3 |
Vaccination With Autologous Dendritic Cells Pulsed With HIV-Antigens for Treatment of Patients With Chronic HIV-Infection
Status |
Completed |
Phase |
Unspecified |
Conditions |
HIV Infections |
Start date |
January 2007 |
End date |
October 2008 |
Study type |
INTERVENTIONAL |
Interventions |
Peptides on autologous Dendritic Cells |
NCT number |
NCT00856154 |
Go to top of page
|
4 |
Dendritic Cells in Lung Cancer
Status |
Completed |
Phase |
Unspecified |
Conditions |
Non Small Cell Lung Cancer |
Start date |
December 2006 |
End date |
November 2009 |
Study type |
INTERVENTIONAL |
Interventions |
Allogeneic Tumour Lysate (MelCancerVac) |
NCT number |
NCT00442754 |
Go to top of page
|
5 |
Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer
Status |
Completed |
Phase |
Unspecified |
Conditions |
Prostatic Cancer |
Start date |
July 2006 |
End date |
May 2010 |
Study type |
INTERVENTIONAL |
Interventions |
Autologous Dendritic Cell |
NCT number |
NCT01171729 |
Go to top of page
|
6 |
Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission
Status |
Completed |
Phase |
Unspecified |
Conditions |
Acute Myeloid Leukemia (AML) |
th width=’25%’>Start date
March 2005 |
End date |
December 2008 |
Study type |
INTERVENTIONAL |
Interventions |
injection of antigen-loaded cultured dendritic cells |
NCT number |
NCT00834002 |
Go to top of page
|
7 |
Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe)
Status |
Completed |
Phase |
Unspecified |
Conditions |
Metastatic Breast Cancer |
Start date |
January 2005 |
End date |
May 2012 |
Study type |
INTERVENTIONAL |
Interventions |
AdHer-2/neu transduced dendritic cells |
NCT number |
NCT00162929 |
Go to top of page
|
8 |
Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells
Status |
Completed |
Phase |
Unspecified |
Conditions |
Melanoma |
Start date |
October 2004 |
End date |
December 2005 |
Study type |
INTERVENTIONAL |
Interventions |
DC/Apo-Nec |
NCT number |
NCT00515983 |
Go to top of page
|
9 |
Administration of Autologous Dendritic Cells (DCs) Infected With an Adenovirus Expressing Her-2
Status |
Completed |
Phase |
Unspecified |
Conditions |
Breast Neoplasms |
Start date |
October 2004 |
End date |
May 2012 |
Study type |
INTERVENTIONAL |
Interventions |
CD34+ derived DCs |
NCT number |
NCT00197522 |
Go to top of page
|
10 |
Dendritic Cell Based Therapy of Malignant Melanoma
Status |
Completed |
Phase |
Unspecified |
Conditions |
Advanced Melanoma |
Start date |
September 2004 |
End date |
April 2010 |
Study type |
INTERVENTIONAL |
Interventions |
tumor antigen loaded autologous dendritic cells |
NCT number |
NCT00197912 |
Go to top of page
|
11 |
Dendritic Cell Based Therapy of Renal Cell Carcinoma
Status |
Completed |
Phase |
Unspecified |
Conditions |
Advanced Renal Cell Carcinoma |
Start date |
September 2004 |
End date |
October 2010 |
Study type |
INTERVENTIONAL |
Interventions |
tumor antigen loaded autologous dendritic cells |
NCT number |
NCT00197860 |
Go to top of page
|
12 |
Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients
Status |
Completed |
Phase |
Unspecified |
Conditions |
Melanoma Stage III or IV |
Start date |
April 2004 |
End date |
Unspecified |
Study type |
INTERVENTIONAL |
Interventions |
autologous dendritic cell vaccine |
NCT number |
NCT00243529 |
Go to top of page
|
13 |
Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients
Status |
Completed |
Phase |
Unspecified |
Conditions |
Melanoma |
Start date |
March 2004 |
End date |
October 2005 |
Study type |
INTERVENTIONAL |
Interventions |
Dendritic cells, Daclizumab |
NCT number |
NCT00847106 |
Go to top of page
|
14 |
Carcinoembryonic Antigen-loaded Dendritic Cells in Advanced Colorectal Cancer Patients
Status |
Completed |
Phase |
Unspecified |
Conditions |
Liver Metastases, Colorectal Cancer |
Start date |
December 2003 |
End date |
November 2010 |
Study type |
INTERVENTIONAL |
Interventions |
CEA-loaded dendritic cell vaccine |
NCT number |
NCT00228189 |
Go to top of page
|
15 |
Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma
Status |
Completed |
Phase |
Unspecified |
Conditions |
Plasmocytoma, Multiple Myeloma |
Start date |
March 2002 |
End date |
March 2004 |
Study type |
INTERVENTIONAL |
Interventions |
autologous idiotype-protein pulsed dendritic cells |
NCT number |
NCT00988312 |
Go to top of page
|
16 |
Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma
Status |
Completed |
Phase |
Unspecified |
Conditions |
Multiple Myeloma and Plasma Cell Neoplasm |
Start date |
August 2001 |
End date |
November 2007 |
Study type |
INTERVENTIONAL |
Interventions |
reverse transcriptase-polymerase chain reaction, polymerase chain reaction, laboratory biomarker analysis, idiotype-pulsed autologous dendritic cell vaccine APC8020, flow cytometry, aldesleukin, recombinant interferon gamma |
NCT number |
NCT00616720 |
Go to top of page
|
17 |
Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection
Status |
Completed |
Phase |
Unspecified |
Conditions |
Melanoma Stage III or IV |
Start date |
September 1999 |
End date |
Unspecified |
Study type |
INTERVENTIONAL |
Interventions |
Peptide-pulsed dendritic cells |
NCT number |
NCT00243594 |
Go to top of page
|
18 |
Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma
Status |
Completed |
Phase |
Unspecified |
Conditions |
Malignant Melanoma |
Start date |
|
End date |
Unspecified |
Study type |
INTERVENTIONAL |
Interventions |
Dendritic Cells (DC) malignant melanoma |
NCT number |
NCT01278940 |
Go to top of page
|
19 |
Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer
Status |
Completed |
Phase |
Unspecified |
Conditions |
Prostate Cancer |
Start date |
|
End date |
Unspecified |
Study type |
INTERVENTIONAL |
Interventions |
Dendritic Cells (DC) prostate |
NCT number |
NCT01278914 |
Go to top of page
|
20 |
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
Status |
Completed |
Phase |
Unspecified |
Conditions |
Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma |
Start date |
|
End date |
Unspecified |
Study type |
INTERVENTIONAL |
Interventions |
dendritic cell-gp100-MART-1 antigen vaccine, sargramostim |
NCT number |
NCT00019890 |
Go to top of page
|